Page last updated: 2024-11-05

thalidomide and Deficiency of Glucose-6-Phosphate Dehydrogenase

thalidomide has been researched along with Deficiency of Glucose-6-Phosphate Dehydrogenase in 2 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19902 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
MOTULSKY, AG1
JOERGENSEN, G1

Reviews

2 reviews available for thalidomide and Deficiency of Glucose-6-Phosphate Dehydrogenase

ArticleYear
PHARMACOGENETICS.
    Progress in medical genetics, 1964, Volume: 23

    Topics: Abnormalities, Drug-Induced; Animals; Dicumarol; Dogs; Drug Hypersensitivity; Drug Tolerance; Ethnol

1964
[PHARMACOGENETICS].
    Die Medizinische Welt, 1964, Jan-04, Volume: 33

    Topics: Abnormalities, Drug-Induced; Atropine; Cleft Palate; Cortisone; Genetics; Glucosephosphate Dehydroge

1964